BYPOVY Trademark

Trademark Overview

On Tuesday, June 24, 2025, a trademark application was filed for BYPOVY with the United States Patent and Trademark Office. The USPTO has given the BYPOVY trademark a serial number of 99250874. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 14, 2025. This trademark is owned by Vertex Pharmaceuticals Incorporated. The BYPOVY trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and dis...
bypovy

General Information

Serial Number99250874
Word MarkBYPOVY
Filing DateTuesday, June 24, 2025
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, October 14, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 19, 2025

Trademark Statements

Goods and Servicespharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and disorders; pharmaceutical preparations for the treatment of inflammation related diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 24, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameVertex Pharmaceuticals Incorporated
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBoston, MA 02210
Party NameVertex Pharmaceuticals Incorporated
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02210

Trademark Events

Event DateEvent Description
Tuesday, June 24, 2025NEW APPLICATION ENTERED
Tuesday, June 24, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, July 14, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, August 13, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 19, 2025PUBLISHED FOR OPPOSITION
Tuesday, August 19, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 14, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 10, 2025ASSIGNED TO EXAMINER
Tuesday, June 24, 2025APPLICATION FILING RECEIPT MAILED

Related Keywords

bypovy treatment preparations pharmaceutical diseases immune disorders autoimmune hemolytic anemia nephropathy